ArticleJournal of controlled release : official journal of the Controlled Release Society2016
Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Formulation considerations in enhancing olfactory mucosal deposition for nose-to-brain drug delivery.Drug delivery and translational research · 2026Review
- Intranasal delivery route for neurodegenerative diseases: recent insights and future directions.Drug delivery and translational research · 2026Review
- Nano-Based Vaccine Delivery Systems: Innovative Therapeutics Against Cancer and Neurological Disorders.International journal of molecular sciences · 2025Review
- Preparation, Stability and In Vitro Antineoplastic Function of Lecithin-Chitosan-Polyethylene Glycol Nanoparticles Loaded with Bioactive Peptides Derived from Phycocyanin.Foods (Basel, Switzerland) · 2025Article
- Maltodextrin-modified lipoplexes for enhanced mucosal penetration and efficient mRNA delivery.Materials today. Bio · 2025Article
- Nanoparticle-Driven Modulation of Mucosal Immunity and Interplay with the Microbiome.Journal of microbiology and biotechnology · 2025Review
- T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii.BMC infectious diseases · 2025Article
- Multilayer Adjuvanted Influenza Protein Nanoparticles Improve Intranasal Delivery and Antigen-Specific Immunity.ACS nano · 2025Article
- Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.Frontiers in immunology · 2025Review
- Human T-cell activation withLife science alliance · 2024Article
- Bacteria Synergized with PD-1 Blockade Enhance Positive Feedback Loop of Cancer Cells-M1 Macrophages-T Cells in Glioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport.Pharmaceutics · 2024Review
- Nanoparticles with a Lipid Core Can Enhance the Infection of Epithelial Cells with an Enterovirus.Intervirology · 2024Article
- A Comprehensive Study on Nanoparticle Drug Delivery to the Brain: Application of Machine Learning Techniques.Molecular pharmaceutics · 2024Article
- Nasal vaccination of six squirrel monkeys (International journal for parasitology. Parasites and wildlife · 2023Article
- Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia.Frontiers in pharmacology · 2023Article
- Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells.International journal of pharmaceutics: X · 2022Article
- Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.Acta pharmaceutica Sinica. B · 2022Review
- Article
- In Vivo Tracking of Bacterial Colonization in Different Murine Models Using Bioluminescence: The Example of Salmonella.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intranasal administration of proteins using nanoparticles is a promising approach for several applications, especially for mucosal vaccines. Delivery of protein within the epithelial barrier is a key point to elicit an immune response and nano-carrier has to show no toxicity. The aim of this work was to elucidate the interactions of cationic porous nanoparticles loaded with protein delivery for antigen delivery in the nose. We investigated the loading, the cellular delivery and the epithelial transcytosis of proteins associated to these nanoparticles containing an anionic lipid in their core (NPL). NPL were highly endocytosed by airway epithelial cells and significantly improved the protein delivery into the cell. In vitro transcytosis studies showed that NPL did not modify the in vitro epithelial permeability suggesting no toxicity of these carriers. Moreover protein and NPL did not translocate the epithelial barrier. In vivo studies demonstrated that NPL prolonged the nasal residence time of the protein and no NPL were found beyond the epithelial barrier in vivo, precluding a negative side effect. All together these results establish the NPL as a bio-eliminable and optimal vaccine carrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.